Josep M. Tabernero

Barcelona, CT 08035, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Co-clinical CT radiomics pipeline to establish candidate imaging biomarkers for colorectal cancer.

Co-clinical CT radiomics pipeline to establish candidate imaging biomarkers for colorectal cancer.

Journal: European journal of radiology

Published: January 27, 2026

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

Journal: ESMO open

Published: June 16, 2025

Two decades of advances in clinical oncology - lessons learned and future directions.

Two decades of advances in clinical oncology - lessons learned and future directions.

Journal: Nature reviews. Clinical oncology

Published: September 10, 2024

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial.

Journal: Nature communications

Published: September 05, 2024

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.

COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.

Journal: British journal of cancer

Published: February 29, 2024

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 08, 2023

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial.

Journal: ESMO open

Published: November 17, 2023

Third-Line Therapy in Metastatic Colorectal Cancer. Reply.

Third-Line Therapy in Metastatic Colorectal Cancer. Reply.

Journal: The New England journal of medicine

Published: July 12, 2023

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 25, 2022

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 10, 2022

Current developments in gastric cancer: from molecular profiling to treatment strategy.

Current developments in gastric cancer: from molecular profiling to treatment strategy.

Journal: Nature reviews. Gastroenterology & hepatology

Published: October 11, 2022

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.

Journal: ESMO open

Published: August 31, 2022

Showing 1-12 of 58

Last Updated: 09/26/2026